PARP1 and head and neck squamous cell carcinoma: The combination of PARP inhibitors with ICIs has also been widely explored in head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, renal cancer, other solid cancers, and lymphoma (Table 1).